Perfil
Tomas Hode is the founder of Immunophotonics, Inc., a company founded in 2009, where he currently holds the title of President, Chief Innovation Officer & Director.
He is also currently working as the Director at the Missouri Biotechnology Association.
Dr. Hode obtained his doctorate degree from the University of Stockholm in 2005.
Cargos activos de Tomas Hode
Empresas | Cargo | Inicio |
---|---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Fundador | 01/01/2009 |
Missouri Biotechnology Association | Director/Miembro de la Junta | - |
Formación de Tomas Hode.
University of Stockholm | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 2 |
---|---|
Immunophotonics, Inc.
Immunophotonics, Inc. Pharmaceuticals: MajorHealth Technology Immunophotonics, Inc. develops proprietary novel drug product for use in a minimally invasive therapeutic cancer vaccine. Its vaccine process under development, inCVAX, is a two injection procedure into one or more selected tumors: The first injection is a needle with an optical fiber (coupled to a laser) that heats selected tumor(s) locally; The second injection is experimental drug product, a proprietary synthesized carbohydrate polymer, that is intended to recruit and activate antigen-presenting cells, potentially triggering a cascade that leads to a systemic anti-tumor immune response. The company was founded by Lu Alleruzzo and Tomas Hode in 2009 and is headquartered in St. Louis, MI. | Health Technology |
Missouri Biotechnology Association |
- Bolsa de valores
- Insiders
- Tomas Hode